Printer Friendly

BioCryst Pharmaceuticals announces public offering of USD45.0m common stock.

M2 PHARMA-March 9, 2017-BioCryst Pharmaceuticals announces public offering of USD45.0m common stock

(C)2017 M2 COMMUNICATIONS

Drugs company BioCryst Pharmaceuticals Inc (NasdaqGS:BCRX) said on Wednesday that it plans to sell USD45.0m of its common stock in a public offering.

The company intends to provide the underwriters with a 30-day option to purchase up to an additional USD6.75m of its common stock.

Proceeds may be used by the company for general corporate purposes, future clinical development of BCX7353, continued development of its second generation HAE compounds as well as for the advancement of its other preclinical rare disease programmes.

Subject to market conditions, there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

JP Morgan Securities LLC is acting as sole book-running manager for the proposed offering.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Mar 9, 2017
Words:155
Previous Article:Innovus Pharma to commercialise Sensum+ in the EU following the CPNP notification.
Next Article:TG Therapeutics to launch public offering of common stock.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters